Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/1999
11/23/1999US5990152 Acid resistant to gastric juice; rapidly dissolves in the duodenum; group 1a and 2a metal salts; ammonium and amine salts; storage stability
11/23/1999US5990150 Heterocyclic derivatives, method of production thereof and pharmaceutical use thereof
11/23/1999US5990149 Photodynamic therapy; using triacid form of the monohydrobenzoporphyrin class; antitumor, carcinogenic, arthritic agents; atherosclerosis; restenosis; blood infections; skin disorders; vision defects
11/23/1999US5990148 Side effect reductions; antiarthritic agents; nonsteroidal antiinflammatory agents
11/23/1999US5990147 H3 receptor ligands of the phenyl-alkyl-imidazoles type
11/23/1999US5990146 Treating protein tyrosine kinase mediated cancer; anticarcinogenic agents; atherosclerosis; restenosis; psoriasis; antiproliferative agents
11/23/1999US5990145 Antiinflammatory,-carcinogenic,-tumor,-metastasis agents; cardiovascular disorders, e.g., arteriosclerosis, restenosis; retinopaathies and nephropathies; osteoporosis
11/23/1999US5990142 Antiinflammatory agents and antiallergens having good oral adsorption and bioavailability; cardiotonic and antiischemic agents
11/23/1999US5990141 Administering 5-methyl-isoxazole-4-carboxylic acid-n-(4-trifluoromethyl)anilide or 2-cyano-3-hydroxy-n-(4-trifluoro-methyl)phenyl-2-butenamide; antitumor,-carcinogenic and proliferative agents; kinase inhibitors
11/23/1999US5990139 Thiazolidinedione derivatives or salts thereof and pharmaceutical compositions containing the same
11/23/1999US5990138 Cyclopentane (ene) heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents
11/23/1999US5990137 Antiinflammation agents; preventing the oxidating burst from phagocytic leukocytes; controlling free radicals in the immune response
11/23/1999US5990136 Isoxazoline derivatives useful as antimicrobials
11/23/1999US5990135 For treating a retroviral infection such as hiv infection; for example 5s-n-((2-pyridinyl)methoxycarbonyl)valinylamino-2-((n-3 -pyridinyl)methoxycarbonyl)amino-4s-hydroxy-1,6-diphenyl-2-azahexane and other compounds of given formula
11/23/1999US5990134 Orally administering droperidol to the migraine patient, in an amount from 0.5 mg to about 20 mg
11/23/1999US5990133 Indole derivatives as 5-HT receptor antagonist
11/23/1999US5990132 Polycyclic systems, and derivatives thereof, as neurotransmitter release enhancers useful in the treatment of cognitive disorders
11/23/1999US5990131 Heterocyclic thioesters and ketones
11/23/1999US5990130 Therapeutic heterocycles
11/23/1999US5990129 Regulation of trka, the receptor for the neurotrophin nerve growth factor (ngf), by the administration of 2-aryl-3-aroylbenzo(b)thiophenes of given formula
11/23/1999US5990128 Administering an antagonist that binds to a human alpha-1c adrenergic receptor with a binding affinity at least 691-fold higher than the binding affinity with which the antagonist binds to a human alpha-1b adrenergic receptor
11/23/1999US5990127 Process for the preparation of 4-(4-(4-(hydroxybiphenyl)-1-piperidinyl)-1-hydroxybutyl)-α,α -dimethylphenylacetic acid and phosphorylated derivatives
11/23/1999US5990126 Quinolinic sulfide derivatives acting as NMDA receptor antagonists and process for preparation thereof
11/23/1999US5990125 NK-1 receptor antagonists for the treatment of cancer
11/23/1999US5990124 Neuromuscular relaxants
11/23/1999US5990123 For treating migraine and cephalic pain, and conditions related to vasodilation; pharmacuetical compositions and methods of synthesis via reductive n-alkylation
11/23/1999US5990122 Substituted in the 7-position by a tricyclic amine radical; reduced genotoxic properties and increased antibacterial activity
11/23/1999US5990121 Use of 1,2-bridged 1,4-dihydropyridines as medicaments
11/23/1999US5990120 Given structure, where a five-membered aza-heterocycle is fused to ring (a) of camptothecin at positions 9 and 10; compounds possess high antitumor activity by inhibition of topoisomerase; methods for their synthesis
11/23/1999US5990117 Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives
11/23/1999US5990116 Trisubstituted phenyl derivatives
11/23/1999US5990114 Administering 1,4-substituted piperazine derivatives of given formula to treat neuromuscular dysfunction of the lower urinary tract; both pre- and post-synaptic antagonism; such as 1-(2-((2-pyridylamino)ethyl)-4-(4-indolyl)piperazine
11/23/1999US5990111 Aldose reductase inhibition in preventing or reversing diabetic cardiomyopathy
11/23/1999US5990110 Method for treating tumors having high LDL requirements employing MTP inhibitors
11/23/1999US5990109 Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors
11/23/1999US5990108 5H,10H-imidazo[1,2-a]indeno[1,2-e]pyrazine-4-one derivatives, preparation thereof, intermediates thereof and drugs containing the same
11/23/1999US5990106 Antibiotics; 3-azabicyclo(3.2.0)hept-3-yl group joined at given position of a pyridonecarboxylic acid residue, such as 7-(1-amino-3-azabicyclo(3.2.0)hept-3-yl)-1-cyclopropyl-6,8-difluoro-1,4 -dihydro-4-oxoquinoline-3-carboxylic acid
11/23/1999US5990105 Possess a selective affinity to 5ht-6 receptors; treating or preventing psychoses, schizophrenia, manic depressions, depressions, neurological disorders, parkinson's, amyotrophic lateral sclerosis, alzheimer's and huntington's disease
11/23/1999US5990104 Inhibiting nmda receptor activation by administering derivatives of given formula, such as 5,6,7,8,9,11,12-heptahydro-3-hydroxy-5-methyl-10-thia-5,11 -methanobenzocyclodecen-13-amine (sulphazocine)
11/23/1999US5990103 Treating psoriasis by topical adminstration of pentoxifylline and diltiazem to a patient; a combination of a compound having a phosphodiesterase-inhibiting action, and a compound which reduces the intracellular calcium content
11/23/1999US5990102 Substituted azetidin-2-ones for treatment of atherosclerosis
11/23/1999US5990100 Composition and method for treatment of psoriasis
11/23/1999US5990099 Treating glc1a glaucoma by administering an angiostatic steroid of given formula
11/23/1999US5990098 Therapeutic use of 1-amino-3-(N,N-dimethylamino)-propylidene-1,1-bisphosphonic acid and its salts
11/23/1999US5990097 Methods of treating asthma with o-desulfated heparin
11/23/1999US5990096 Formulations containing hyaluronic acid
11/23/1999US5990095 Use of hyaluronic acid and forms to prevent arterial restenosis
11/23/1999US5990093 Treating hepatitis b virus (hbv) infections by administering a 5'-phospholipid prodrug of beta-l-2',3'-dideoxyadenosine 5'-monophosphate of given structure optionally with other anti-hbv agents, such as carbovir or 3tc
11/23/1999US5990088 Method for treating kaposi's sarcoma with antisense oligonucleotides
11/23/1999US5990086 Therapeutic uses of BPI protein products for human meningococcemia
11/23/1999US5990083 Composition for reducing cu/zn superoxide dismutase-1 enzyme degradation by inhibiting multicatalytic protease; treating muscle wasting diseases associated with low superoxide dismutase-1 enzyme activity
11/23/1999US5990080 Use of protein S-100-b in medicines containing the protein S-100b
11/23/1999US5990078 Contacting sample of neural tissue with: estrogen to increase the level of neurotrophin receptors, and a neurotrophin to increase the level of estrogen receptors
11/23/1999US5989920 Receptor binding assay for screening drugs which bind to human or rat y5 receptor by contacting nonneuronal cells transfected with vector having sequence coding for receptor and detecting binding; treatment of obesity, eating disorders
11/23/1999US5989907 Methods and compositions for calcium binding proteolipid encoding nucleic acids
11/23/1999US5989858 Dead-type ATP-dependent RNA helicase (DbpB) from Staphylococcus aureus
11/23/1999US5989834 Contacting nonneuronal cells transfected with vector; gene expression
11/23/1999US5989832 Method for screening for non-tetracycline efflux pump inhibitors
11/23/1999US5989803 Method for treating a subject suffering from a condition associated with an extracellular zinc sphingomyelinase
11/23/1999US5989592 Inhibition of complement pathway by sea cucumber fractions
11/23/1999US5989591 Dosage unit containing poloxamer and sucrose overcoat
11/23/1999US5989586 Two-phase matrix for sustained release drug delivery device
11/23/1999US5989585 Transdermal therapeutic system (TTS) containing vitamin E for the treatment of drug dependency
11/23/1999US5989583 Solid lipid compositions of lipophilic compounds for enhanced oral bioavailability
11/23/1999US5989582 Administration of ketamine for detoxification and to treat substance addiction, and compositions therefor
11/23/1999US5989581 Thermoplastic polymer core and skin containing steroidal progestogenic compound and steroidal estrogenic compound
11/23/1999US5989578 Associations of active principles containing clopidogrel and an antithrombotic agent
11/23/1999US5989574 Administering composition containing zinc acetate and depletion-preventing dosage of copper gluconate
11/23/1999US5989571 Contact dermatitis pharmaceutical preparation with anti-histamine and anti-inflammatory
11/23/1999US5989566 Stable vaccine compositions for parenteral administration, a method for their use, and a process for their preparation
11/23/1999US5989557 Process for extracting polyphenol fractions of tea and compositions produced therewith
11/23/1999US5989553 Expression library immunization
11/23/1999US5989539 Compounds and compositions for delivering active agents
11/23/1999US5989522 Anti-mycotic drug and ethyl cellulose to provide sustained release
11/23/1999US5988870 Apparatus and method for diluting nasal sprays containing addictive compounds
11/23/1999CA2207694C Process for preparing sildenafil
11/23/1999CA2167559C Process for drying hydrophobic amino acids with improved process for increased bulk density
11/23/1999CA2148109C 1.alpha., 24-(oh)2-v.d.3 emulsion composition
11/23/1999CA2145618C Use of aminoglycosides to protect against excitotoxic neuron damage
11/23/1999CA2116685C (-)-ritodrine
11/23/1999CA2062094C Method of treating mania
11/23/1999CA2015919C Cleaning compositions
11/23/1999CA2011587C Nerve growth factor secretion inducing composition
11/23/1999CA2006184C Prolonged release composition based on trimebutine and process for the preparation thereof
11/23/1999CA2001167C Substituted 2-aminothiazoles
11/23/1999CA1340825C Hyaluronic acid fraction for use as a drug delivery system for medicaments
11/22/1999CA2272639A1 Improved drug formulations
11/21/1999CA2270687A1 Use of a peptide compound in the treatment of systemic lupus erythematosus
11/21/1999CA2238162A1 Tricyclic spiro compounds as 5ht1d receptor antagonists
11/20/1999CA2277490A1 Use of substituted 4-biarylbutyric acids and derivatives for the treatment of fibrotic diseases
11/19/1999CA2237915A1 Osteoporosis treatment
11/18/1999WO1999058706A1 Novel method for preparing synthesis intermediates
11/18/1999WO1999058694A1 Methods of forming protein-linked lipidic microparticles, and compositions thereof
11/18/1999WO1999058684A2 Compounds from moraxella catarrhalis
11/18/1999WO1999058678A2 Antibodies to dendritic cells and human dendritic cell populations and uses thereof
11/18/1999WO1999058658A2 Expression vectors for stimulating an immune response and methods of using the same
11/18/1999WO1999058572A1 Binding molecules derived from immunoglobulins which do not trigger complement mediated lysis
11/18/1999WO1999058555A2 Water-soluble pro-drugs of 2,6-diisopropylphenol analogues
11/18/1999WO1999058549A1 Meiosis regulating compounds
11/18/1999WO1999058545A1 Process for preparation of 4,5-epoxymorphinan-6-oxyglucuronides
1 ... 6408 6409 6410 6411 6412 6413 6414 6415 6416 6417 6418 6419 6420 6421 6422 6423 6424 6425 6426 6427 6428 ... 7860